Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Stock Crosses Below Two Hundred Day Moving Average - Here's What Happened

Novozymes A/S logo with Basic Materials background

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report)'s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $59.69 and traded as low as $57.19. Novozymes A/S shares last traded at $59.31, with a volume of 96,785 shares trading hands.

Novozymes A/S Stock Performance

The company has a fifty day moving average of $58.55 and a two-hundred day moving average of $59.48. The company has a market cap of $28.80 billion, a PE ratio of 38.92, a price-to-earnings-growth ratio of 3.87 and a beta of 0.91.

Novozymes A/S Increases Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Monday, April 7th will be paid a dividend of $0.3758 per share. This is a positive change from Novozymes A/S's previous dividend of $0.17. The ex-dividend date of this dividend is Monday, April 7th. Novozymes A/S's payout ratio is 47.47%.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Featured Stories

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy Early: 3 Tech Trends With Millionaire-Making Potential
SMCI Stumbles on Earnings: Why Some Investors Still Want In
5 Stocks to BUY NOW in May 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines